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the pancreas. Treatment seems to be related to the associa-
tion with other neoplasms, tumor extension at the time of 
diagnosis and the possibility to perform a radical resection. 
The common embryologic origin of the pancreas and liver, 
together with peculiar environmental factors, may explain 
the development of pancreatic HCs.  © 2013 S. Karger AG, Basel 
 Introduction 
 Hepatoid carcinoma (HC) is a neoplasm exhibiting 
features of hepatocellular carcinoma (HCC) in terms of 
morphology and immunohistochemistry which grows 
outside the liver  [1–3] . The first case was reported by Ishi-
kura et al. [4] and concerned HC in the stomach. Since 
then, its occurrence has been described in gonadal yolk 
sac as well as in several non-germ cell origin primary sites, 
including esophagus, ampulla of Vater, colon, lung, gall-
bladder, adrenal gland, kidney, urinary bladder, ovary, 
uterus, vagina, and testicle  [1–16] . Microscopic ‘stigmata’ 
of those origins are typically detectable in tumor focal ar-
eas.
 HC, much like HCC, is often associated with elevated 
serum α-fetoprotein (AFP) levels and usually presents in 
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 Abstract 
 Background: Hepatoid carcinomas (HCs) are extrahepatic 
neoplasms exhibiting features of hepatocellular tumors in 
terms of morphology and immunohistochemistry. They 
have been described in several organs, most notably in the 
stomach and ovary. They can present in pure forms or in as-
sociation with other morphological aspects, such as endo-
crine tumors or ductal adenocarcinomas. The aim of this re-
view is to describe aspects of hepatoid adenocarcinoma of 
the pancreas with regard to epidemiology, diagnosis, and 
treatment.  Methods: The PubMed database was searched 
for publications addressing hepatoid adenocarcinoma of 
the pancreas. We have searched for articles including the fol-
lowing keywords: ‘pancreatic hepatoid carcinoma’, ‘ectopic 
liver cancer’ and ‘rare pancreas neoplasm’ published to date. 
As references, we used case reports and review articles.  Re-
sults: Pancreatic forms of HCs are extremely uncommon: 
only 22 cases have been reported.  Conclusions: The possibil-
ity of an HC of the pancreas should be considered in the dif-
ferential diagnosis of an uncommon pathological mass of 
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elderly individuals  [16] . Since the liver, pancreas and 
stomach all originate from the primitive embryonic fore-
gut, it is likely that these organs retain a latent ability to 
produce AFP, or that the tumor cells differentiate into 
hepatic cells and intestinal mucosal cells. Recently, the 
absence in serum of the protein induced by vitamin K or 
elevated antagonist II (PIVKA-II), which is used for early 
diagnosis of HCC, has been reported with HC  [16, 17] .
 These tumors can present in pure forms or in associa-
tion with other morphological aspects, such as endocrine 
tumors or ductal adenocarcinomas. This hepatoid differ-
entiation within the pancreas can be explained by the 
common embryologic foregut derivation of the pancreas 
and liver. In this report, we describe the clinical, cytolog-
ic and histopathologic features of a pure pancreatic HC. 
We reviewed published literature on HC of the pancreas 
to interpret diagnostic, treatment and prognostic issues, 
as well as possible etiological hypotheses of this rare dis-
ease.
 Etiology and Cell Origin 
 Ectopic liver tissue is reported in several sites, such as 
the gallbladder, hepatic ligaments, omentum, retroperito-
neum and thorax  [18] . This suggests HC to be a tumor 
originating from ectopic pancreatic liver tissue  [19, 20] . 
However, controversy still surrounds the etiology and the 
pathogenesis of HC of the pancreas. Early or late develop-
ment of abnormalities on ectopic liver tissue may indeed 
occur, even though pancreatic liver tissue has never been 
described in the literature. Not even the 2 published papers 
supporting such hypothesis reported any ectopic normal 
liver tissue nearby the cancer area  [19, 20] . Pancreas-to-
liver ‘transdifferentiation’ has been assessed on animal 
models since 1991  [21] , with many authors focusing on the 
histogenic mechanism of hepatocyte differentiation in the 
pancreas of the rat model following copper depletion-re-
pletion  [22] . Complete hepatocyte function following the 
switch has also been described as the pancreas of adult 
mice contains hepatocyte progenitor cells capable of sig-
nificant therapeutic liver reconstruction  [22] . Several au-
thors claim this would be the key event of the pancreatic 
development of HCs  [23–26] . Another pathogenetic 
mechanism relies on the common origin of pancreatic and 
liver tissue from the posterior foregut endodermic cells, 
keeping at a certain point distinct differentiation path-
ways. Pancreatic multipotent cells normally suppress he-
patocytic differentiation genes, which could be activated 
during tumor genesis or for particular environmental con-
ditions  [23] . As previously suggested by other authors, the 
presence of a common multipotent/stem cell in the coex-
istence of peculiar environmental conditions (e.g. produc-
tion-specific cytokines by the intrapancreatic common 
bile duct) may be implicated in the hepatoid differentia-
tion of pancreatic tumors. In this meaning, pancreatic HCs 
may be seen as a possibility in the wide spectrum of pan-
creatic pluriphenotypical differentiation.
 Discussion and Review of the Literature 
 Epidemiology 
 The reported incidence of ectopic liver tissue in differ-
ent organs ranges between 0.24 and 0.47%  [18, 27] ; how-
ever, the true incidence of HC of the pancreas is still not 
known since presentation is often silent until symptoms 
of compression, pain or bleeding occur, and it usually has 
an aggressive course  [19, 49] .
 Patient Characteristics and Clinical Presentation 
 Table 1 summarizes patient characteristics and main 
features at presentation in hepatoid adenocarcinoma, as 
reported in the literature. Patients’ mean age was 52.9 
years (range 21–80), about 15 years less than the age of 
patients with pancreatic ductal adenocarcinoma. Eight 
patients were female (36.4%), while 14 were male (63.6%).
 Generally, HC is associated with a very poor prognosis 
due to its aggressive course  [34, 36] . The diagnosis is typ-
ically made incidentally, since lesions usually remain si-
lent until symptoms of compression, pain or bleeding oc-
cur  [19] .
 Table 2 outlines features characterizing the tumor in 
reported literature. There was no apparent predilection 
for location in the pancreas, and sizes ranged from 0.5 to 
11 cm in the greatest dimension of tumor. Most cases 
were asymptomatic or incidentally discovered (31.3%), 
the most common presenting symptoms were pain, either 
back or epigastric (27.3%), followed by jaundice (18.2%), 
nausea/vomiting (18.2%) and weight loss (13.6%). Such 
data are comparable to those related to other pancreatic/
periampullary malignant tumors. Of particular interest, 2 
patients (9.1%) complained of clinical symptoms refer-
able to a concomitant pancreatic neuroendocrine tumor 
(1 insulinoma and 1 glucagonoma, respectively), un-
derlining the possible association of pancreatic HC with 
other pancreatic neoplasms. Elevated AFP serum levels 
might be present at time of diagnosis in all HCs, despite 
tumor primary site  [7, 8, 11, 12, 28–33, 34] . Our review of 
pancreatic forms indeed reports a rate of 54.5% (12 out of 
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22 cases), bearing in mind that 3 papers did not report or 
did not assess AFP levels of their cases. However, AFP is 
not a specific marker: it can be elevated in acinar as well 
as in ductal, neuroendocrine and undifferentiated carci-
nomas of the pancreas  [35] and, at the same time, it could 
be normal in the presence of an HCC. AFP serum level 
might therefore be more useful during the follow-up of 
surgically resected producing tumors. The radiological 
appearance of a diagnosed pancreatic HC is shown in  fig-
ure 1 , with an abdominal MRI revealing a 10-cm mass in 
the pancreatic head.
 PIVKA-II, a tumor marker for HCC which was first 
described by Liebman in 1984, has become increasingly 
popular as a more specific and diagnostic serum marker 
than AFP  [37–41] . Very rarely do malignant tumors oth-
er than HCC produce PIVKA-II, and it was discovered to 
be elevated in the case of HC of the pancreas  [24] . Other 
tumor markers used for diagnosis include immunoreac-
tivity with polyclonal antibodies against CEA, hepato-
cyte-specific Hep-Par1 antibody and albumin mRNA de-
tected by in situ hybridization  [28] .
 Table 1. Patient characteristics and main features at presentation of hepatoid adenocarcinoma of the pancreas in the literature
Case First author Ref. Year Age Sex Presentation Serum AFP
levels at
diagnosis
CEA Location
(pancreas)
Size, cm Other component
1 Hruban 36 1987 53 F subcutaneous fat necrosis normal N/A tail 1 acinar
2 Gardiner 2 1992 61 F jaundice and fatigue elevated elevated head N/A ductal adenocarcinoma
3 Tanno 23 1999 65 F epigastric and back pain, anorexia,
weight loss
elevated elevated body-tail 6 × 5 ductal adenocarcinoma
4 Yano 34 1999 57 M jaundice, epigastric pain, vomiting
and fever
elevated elevated head 9 × 7×5 ductal adenocarcinoma
5 Paner 33 2000 57 M vomiting, diarrhea, weight loss,
skin rash
elevated elevated tail 6 × 4×3.5 glucagonoma
6 Paner 33 2000 28 M abdominal and back pain elevated elevated multifocal 8 × 8×6 ductal adenocarcinoma
7 Lam 30 2001 64 F hypoglycemia and recurrent
episodes of nocturnal sweating
elevated N/A tail 7 × 4×4 insulinoma
8 Cuilliere 46 2002 70 M incidental (asymptomatic) normal N/A body 3 serous microcystic 
adenoma
9 Hughes 11 2004 51 M gastrointestinal bleeding normal normal tail 6 × 5.5 × 5.5 no
10 Matsueda 24 2006 49 F weight loss elevated normal widespread N/A no
11 Shih 43 2006 32 M incidental (asymptomatic) normal elevated tail 7 no
12 Oh 25 2006 21 M incidental (asymptomatic) elevated N/A head 3 × 3×3 neuroendocrine
13 Hameed 28 2007 41 F jaundice, abdominal pain elevated elevated head 4.5 × 4×3 endocrine
14 Cardona 19 2007 58 M back and flank pain normal N/A body 3.3 × 2.5 × 2.5 no
15 Kubota 20 2007 56 M diabetes N/A N/A tail 6.3 × 6.2 no
16 Liu 44 2007 80 M nausea, diarrhea, weight loss normal N/A head 5 × 5×6 no
17 Jung 26 2010 46 M dyspepsia elevated elevated head 8 × 9 neuroendocrine
18 Petrelli 47 2011 37 M incidental (abdominal mass) N/A normal body 11 no
20 Kai 49 2012 79 F incidental (asymptomatic) elevated elevated tail 7 no
21 Kelly  48 2012 53 F severe epigastric pain elevated N/A body-tail N/A no
22 Huang 45 2012 52 M incidental (asymptomatic) N/A elevated head 0.5 nodule neuroendocrine
 CEA = Carcinoembryonic antigen; N/A = not available.
Table 2.  Outline of the main features characterizing presentation 
in 22 adult patients as reported in the literature
Symptoms
Incidental 31.8%
Pain (abdominal/back) 27.3%
Abdominal symptoms 18.2%
Jaundice 18.2%
Weight loss 13.6%
Site
Head 31.8%
Tail 31.8%
Body 18.2%
Diffuse or multifocal 13.6%
Size range, cm 0.5 – 11
Age, years
Range 21 – 80
Average 52.3
Gender
Female:male 8:14
Metastatic 45.4%
Elevated AFP 57.1%
Elevated CEA 47.6%
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 Histological Features 
 In the literature, there were 10 reported cases of ‘pure’ 
HC  [11, 19, 20, 24, 26, 34, 43, 44, 47–49] and 11 of HC as-
sociated with another component. The admixed were as 
follows: 4 cases with neuroendocrine carcinoma  [25, 26, 
30, 45] , 1 case associated with malignant glucagonoma 
 [33] , 1 with malignant insulinoma  [28] , 1 case with acinar 
 [36] and 4 with ductal adenocarcinoma  [33] . Cuilliere et 
al. [46] documented the only reported case of a benign 
hepatocellular neoplasm arising in the pancreas, which 
was an encapsulated solid adenoma in the pancreas that 
showed exclusively hepatocellular differentiation. The 
tumor was considered benign due to lack of mitoses, nu-
clear atypia, and vascular invasion. In cases where other 
components are associated with HC, the histological and 
immunohistochemical patterns of expression of these tu-
mors would also be identified.
 Gross examination of the tumor could present a lobu-
lated gray-greenish lesion, which is a typical aspect of 
HCC. Histological diagnosis of a pure form of HC may be 
straightforward.  Figure 2 shows a sectioning of resected 
specimen showing a 5-cm pseudolobulated greenish mass 
of a pancreatic hepatoid adenocarcinoma in the head of 
the organ. Thickened cell plates with round nuclei and 
eosinophilic cytoplasm in a predominantly trabecular 
pattern (as well as aspect of lymphatic-vascular invasion) 
represented the typical microscopic appearance of the tu-
mor. The more frequent immunohistochemical stains 
used for detection of HC are cytoplasmic positive reac-
tion of cells that strongly express AFP, hepatocyte anti-
gen, cytokeratin, and positive proteins include keratin/
cytokeratin, cell adhesion molecule 5.2/AE, albumin, 
ACT, prealbumin, α 1 -antitrypsin protease inhibitor, and 
transferrin. This characteristic molecular marker expres-
sion pattern suggests HC  [26] .
 The evidence of medium to large polygonal cells, eo-
sinophilic to clear cytoplasm with vesicular nuclei and 
prominent nucleoli growing in a perisinusoidal pattern, 
along with the demonstration of the presence of bile and 
an immunohistochemical profile characteristic of HCC 
represent pathognomonic features  [42] .  Figure 3 shows 
the hematoxylin and eosin microscopic image of a cyto-
 Fig. 1. Abdominal MRI of a well-delineated solid mass 10 cm in 
diameter involving the body of the pancreas. 
 Fig. 2. Sectioning of resected specimen showing a 5-cm pseudo-
lobulated greenish mass of the pancreatic head. 
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logic slide obtained by scraping of the fresh surgical spec-
imen, showing the histologic appearance of the lesion. 
 Figure 4 shows the immunohistochemistry with immu-
nolabeling for anti-hepatocyte, for CD56, for CD10 and 
negative immunostaining for synaptophysin.
 Differential Diagnosis 
 The histologic differential diagnosis of HC of the pan-
creas depends mostly on the degree of hepatoid differen-
tiation, and the amount of the non-hepatoid component, 
if any. When diagnosing primary pancreatic HC, it is im-
portant to exclude metastatic HCC and ectopic HCC by 
clinical and pathological examination.
 No standardized criteria for diagnosing HCs have 
been established, but morphological and immunohisto-
chemical similarity to HCC is required. Morphological 
features may suggest hepatocellular differentiation, and 
bile production is confirmatory, but is usually only seen 
in well-differentiated tumors. The incidence of HCC 
spreading to the pancreas is only 2.7–5.6%, and the me-
tastasis is usually a late finding  [39, 42] ; however, meta-
static HCC must be considered. Long-term follow-up is 
needed to exclude the possibility that the pancreatic tu-
mor represents a metastasis from the liver.
 HC and HCC share numerous clinicopathological fea-
tures, such as morphology, elevated serum AFP and AFP-
positive staining on histology, canalicular-pattern CEA, 
and α 1 -antitrypsin. This makes differential diagnosis par-
ticularly challenging with an unknown primary tumor. 
Differentiating between the two can be made essentially 
by immunohistochemistry, with an expressed profile of 
CK  [47] .
a b
c
 Fig. 3.  a Hematoxylin and eosin microscopic image of a cytologic 
slide obtained by scraping of the fresh surgical specimen, showing 
trabecular clusters of polygonal cells with round nucleus and small 
but evident central nucleolus and eosinophilic huge cytoplasm.
 b Hematoxylin and eosin low-magnification microscopic image of 
the border of the lesion (right) in relationship to normal pancreas 
tissue (left).  c Hematoxylin and eosin high-magnification micro-
scopic image showing pigmented deposits, brownish or greenish 
ones, at least in part made of bile. 
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 If bile production cannot be identified histologically, 
then the differential diagnosis would also include other 
pancreatic tumors that have large eosinophilic tumor 
cells, such as intraductal oncocytic papillary neoplasms, 
pancreatoblastoma, and acinar cell carcinoma  [24] .
 Treatment Modalities and Long-Term Prognosis 
 The treatment associated with the best disease-free 
survival remains to be radical surgical resection  [11, 19, 
20, 25, 26, 30, 33, 43, 45–49] . Of the 22 adult cases report-
ed in the literature, 10 (46%) had distant metastases at 
presentation, 16 (87%) underwent surgery and 9 (41%) 
died of the disease  [2, 23, 28, 33, 34, 47, 48] . The mean 
survival rate of patients that died of disease was 18 months. 
The role of adjuvant therapy after surgery resection is still 
unclear and is based on few experiences as shown in  ta-
ble 3 . Although some authors have advocated adjuvant 
chemotherapy because of the metastatic potential of the 
tumor  [28] , others have indicated no discernible events 
 [24, 28, 33] . A certain degree of response to chemothera-
py with long-term survival was reported in locally unre-
sectable, metastatic or recurrent disease  [30, 33] . There-
fore, aggressive treatment seems warranted even in the 
case of locally advanced diseases, and resection of metas-
tases may be considered as well  [24] . Due to its rarity, the 
natural history and prognosis of the disease cannot be 
accurately predicted. The longest period achieved with-
out any adjuvant therapy was 48 months  [43] . The longest 
a b
c d
 Fig. 4.  a Immunolabeling for anti-hepatocytes.  b Immunolabeling for CD56.  c Immunolabeling for CD10.
 d Negative immunostaining for synaptophysin. 
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disease-free interval after resection reported in the liter-
ature is 102 months with adjuvant chemotherapy  [33] . 
This suggests chemotherapy may have a role in recurrent, 
residual unresectable and metastatic disease, but data are 
limited.
 So far, the limited data suggest that around 50% of 
adult patients will die of this disease within 3 years from 
initial diagnosis. Owing to its rarity, the treatment ap-
proach is far from being standardized. It is suggested 
therefore that surgical resection is the treatment of choice 
whenever possible, and complete resection of the tumor 
appears to be the best option; however, long-term follow-
up is warranted since recurrence seems common.
 Survival and Outcome 
 Pancreatic forms of HC are extremely uncommon, 
with 22 cases  [2, 11, 19, 20, 23–26, 28, 30, 33, 34, 43, 44–
49] being reported at the time of writing this review. Lit-
erature review shows divergent results in terms of sur-
vival. Thirteen reports have long-term follow-up (over 1 
Table 3.  Therapy and outcome of hepatoid adenocarcinoma of the pancreas as reported in the literature
Case First author Ref. Year Metastasis Therapy Follow-
up,
months
Out-
come
1 Hruban 36 1987 liver N/A 2.75 DOD
2 Gardiner 2 1992 no N/A N/A N/A
3 Tanno 23 1999 liver N/A 6 DOD
4 Yano 34 1999 liver N/A 3 DOD
5 Paner 33 2000 liver distal two thirds pancreatectomy with splenectomy and biopsy of a liver nodule → course of 
marked disease remissions and exacerbations → intravenous di-amino triazeno-imidazole 
carboxamide, 400 mg for 5 days every 6 weeks → clinical improvements and decreased 
circulating glucagon → patient survived for 8.5 years and died of a widespread hepatoid islet 
cell carcinoma
102 DOD
6 Paner 33 2000 widespread unresectable tumor on exploration → chemotherapy regimens provided no discernible effect 14 DOD
7 Lam 30 2001 liver distal pancreatectomy with splenectomy → TA chemoembolization of liver mets → six courses 
5 FU + streptozocin alternating with adriamycin and dacarbazine → tumor regression of >50% 
and normoglycemic 16 months after treatment → liver metastases progressed + recurrent 
hypoglycemia and hyperinsulinemia
22 DOD
8 Cuilliere 46 2002 no a distal two thirds pancreatectomy with splenectomy 12 ANED
9 Hughes 11 2004 no conventional Whipple’s operation 14 ANED
10 Shih 43 2006 no distal pancreatectomy and splenectomy → gemcitabine 600 or 800 mg/body weekly or 
biweekly for 26 months → right lobectomy of the liver at 39 months → increase in tumor size + 
elevated AFP
18 ANED
11 Matsueda 24 2006 liver (at 12
months FU)
total pancreatectomy 48 alive
12 Oh 25 2006 no pylorus-preserving Whipple’s operation 7 ANED
13 Hameed 28 2007 liver pancreatoduodenectomy → several cycles of cisplatin and irinotecan for 7 months → 
abdominal CT showed retroperitoneal lymphadenopathy + liver masses on FNA proved 
metastatic disease at 12 months follow-up → additional courses of systemic chemotherapy and 
chemoembolization of liver lesions → disease progressed with deteriorated general condition
26 DOD
14 Cardona 19 2007 no distal pancreatectomy and splenectomy 15 ANED
15 Kubota 20 2007 no distal pancreatectomy and splenectomy 36 ANED
16 Liu 44 2007 widespread a simple tumorectomy and partial transverse colon resection (diffuse disease, patient believed 
intolerable of radical surgery because of age)
6 ANED
17 Jung 26 2010 no Whipple operation (radical pancreaticoduodenectomy) → aggressive disease progression 4 ANED
18 Petrelli 47 2011 liver, lungs advanced at presentation → patient refused classical chemotherapy but agreed to therapy with 
sorafenib (dosage of 400 mg was administered b.i.d. albumin and diuretics)
12 DOD
20  Kai 49 2012 no distal pancreatectomy and splenectomy combined with resection of the left adrenal gland and 
total gastrectomy (penetrating tumor) → liver metastases were detected at 1 month after 
operation
2 DOD
21 Kelly 48 2012 no distal pancreatectomy and splenectomy → residual tumor at 3 months → completion of 
pancreatectomy → adjuvant gemcitabine and carboplatin chemotherapy → developed liver 
metastases
22 alive
22 Huang 45 2012 no pylorus-preserving Whipple’s operation → oral sunitinib 16 ANED
 ANED = Alive, no evidence of disease; DOD = died of disease; N/A = not available.
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year)  [19, 20, 24, 28, 30, 33, 43, 46] , with 1 patient disease 
free at 3-year postoperative follow-up  [20] . Among the 22 
reported cases of HC of the pancreas, 2 patients that un-
derwent surgical resection had a good outcome; 1 patient 
survived for 18 months  [24] and another patient died 8.5 
years later. Results are shown in  table 3 .
 Table 3 summarizes therapy and related outcome of 
adult pancreatic hepatoid adenocarcinoma. Patients pre-
senting with metastatic HCs at the time of diagnosis 
showed the typical pattern of liver involvement from up-
per gastrointestinal tract malignancies, with a 10.5 months 
median of overall survival (range 1–102). Petrelli et al. 
[47] reported a case of a 37-year-old patient having a pan-
creatic mass and multiple liver nodules and treated with 
multi-target tyrosine kinase inhibitor sorafenib. Off-label 
chemotherapy resulted in 7 months of progression-free 
survival. The patient eventually died of disease 1 year after 
the diagnosis. Although evidence is limited, one may 
speculate that pancreatic HC shows the typical features of 
an aggressive malignant upper gastrointestinal tumor 
 [47] .
 With regard to pure forms, the one reported by Yano 
et al. [34] had the worst outcome after radical surgery (5 
months). Such outcome may be correlated with the ex-
tension of the neoplasm at the time of diagnosis and, in 
particular, with the reported massive vascular invasion. 
On the opposite side of the spectrum, Cuilliere et al. [46] 
report a good outcome after excision of a small, inciden-
tally discovered and exempted from vascular invasion tu-
mor (at 12 months after surgical resection, the patient is 
alive and disease free). Long-term outcome of HC ap-
pears unclear due to its rarity and possible heterogeneity. 
In the case of a double component, a concomitant ductal 
adenocarcinoma or a poorly differentiated endocrine tu-
mor will reasonably affect the prognosis, more than the 
hepatoid component. Pure forms represent on the other 
hand tricky entities that should be considered on a case-
by-case basis.
 With regard to chemotherapeutic agents, fluorouracil 
can be used to provide some symptom control, and gem-
citabine has proved useful as a palliative agent in patients 
with advanced pancreatic cancer. Doxorubicin-based 
regimens have the greatest efficacy but little impact on 
overall survival in HCC, indicating its minimal respon-
siveness to systemic chemotherapy. Likewise, as chemo-
therapeutic agents have limited effectiveness against tu-
mors of the pancreas or liver, no standard therapy exists 
for treating hepatoid tumors  [47] .
 Conclusion 
 Pancreatic HC is an extremely uncommon neoplasm. 
Preoperative diagnosis is challenging since diagnosis de-
pends mainly on specific pathological findings, even with 
appropriate imaging and cytological examination. This 
neoplasm can share microscopic features with other more 
common pancreatic tumors, such as neuroendocrine tu-
mors. Both the surgeon and pathologist should consider 
this entity in differential diagnosis of ‘unusual’ mass 
forming pancreatic tumors. Biological behavior of pure 
forms seems to be more indolent in comparison with het-
erogeneous tumors. Owing to its rarity, the treatment ap-
proach is far from being standardized; however, surgical 
resection is the treatment of choice whenever possible. 
Surgical excision may be associated with good long-term 
results, but further studies and longer follow-up are need-
ed to correctly assess prognostic features. While complete 
resection of the tumor appears to be the best option, che-
motherapy and radiotherapy may have a role in recur-
rent, residual unresectable and metastatic disease, but 
data are limited.
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